Evolving epidemiology of malignancies in HIV

Current Opinion in Oncology

Volumn 20, Issue 5, 2008, Pages 534-540

  Bonnet, Fabrice ^a,b,c,d   Chêne, Geneviève ^a,b  

^a INSERM   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d HÔPITAL SAINT ANDRÉ   (France)

Author keywords

AIDS; AIDS cancer; Cancer; Epidemiology; HIV; Non AIDS cancer

Indexed keywords

ANTIRETROVIRUS AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; PREDNISONE; RITUXIMAB; VINCRISTINE; WART VIRUS VACCINE;

ALCOHOL CONSUMPTION; ANUS CANCER; BRAIN LYMPHOMA; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CAUSE OF DEATH; CONJUNCTIVA CANCER; CONJUNCTIVA TUMOR; EVIDENCE BASED MEDICINE; HEAD AND NECK CANCER; HIGH RISK POPULATION; HOMEOPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; KAPOSI SARCOMA; KIDNEY CANCER; LEUKEMIA; LIP CANCER; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; MELANOMA; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEMINOMA; SMOKING CESSATION; UTERINE CERVIX CANCER; VIRUS INFECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; NEOPLASM;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; NEOPLASMS;

EID: 59649111254     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32830a5080     Document Type: Review

References (75)

1. Lewden C, May T, Rosenthal E, et al. Evolution of causes of death among adults infected by the human immunodeficiency virus (HIV) between 2000 and 2005. The 'Mortalite 2000 & 2005' surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr (in press). A large national study describing the evolution of the causes of death between 2000 and 2005 in France. AIDS and non-AIDS malignancies accounted for 35% of the total causes of death.
2. Bonnet F, Chêne G, Thiebaut R, et al. Trends and determinants of severe morbidity in HIV-infected patients: ANRS CO3 Aquitaine Cohort, 2000-2004. HIV Med 2007; 8:547-554.
3. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41:1-19.
4. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
5. CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 2000; 355:1158-1159.
6. Lewden C, Salmon D, Morlat P, et al. Causes of death among HIV-infected adults living in industrialized countries. A national study over the year 2000. Int J Epidemiol 2005; 34:121-130.
7. Bonnet F, Lewden C, May T, et al. Malignancies-related causes of death at the era of HAART: the French survey 'Mortalite 2000'. Cancer 2004; 101:317-324.
8. Bonnet F, Morlat P, Chêne G, et al. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy. HIV Med 2002; 3:195-199.
9. CDC. Revision of the case definition of acquired immunodeficiency syndrome for national reporting. MMWR 1985; 34:373-375.
10. International Collaboration on HIV and Cancer. HAART and incidence of cancer in HIV-infected adults. J Natl Cancer Inst 2000; 92:1823-1830.
11. Besson C, Gou bar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001; 98:2339-2344.
12. Levine AM. Acquired immunodeficiency syndrome related lymphomas: clinical aspects. Semin Oncol 2000; 356:291-296.
13. Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001; 98:3406-3412.
14. Cascade Collaboration. Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion: incidence and predictors. AIDS 2004; 18:673-681.
15. Polesel J, Clifford GM, Rickenbach M, et al. Non-Hodgkin lymphoma inci-dence in the Swiss HIV cohort study before and after highly active antiretroviral therapy. AIDS 2008; 22:301-306. The largest study about NHL incidence showing that highly active antiretroviral therapy greatly reduced the incidence of NHL in people living with HIV.
16. Bruyand M, Thiebaut R, Lawson-Ayayi S, et al. Immunodeficiency and risk of AIDS-defining and non-AIDS-defining cancers: ANRS CO3 Aquitaine Cohort, 1998 to 2006 [abstract 15]. In: 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston. A large cohort study showing that a longer exposure to uncontrolled HIV-RNA was associated with a higher risk of AIDS-defining cancers independent of CD4 cell count, and that prolonged immunodepression was associated with a higher risk of both AIDS and non-AIDS malignancies.
17. Zoulafy A, Stelbrink HJ, an der Heiden M, et al. Insufficient virus suppression during HAART is a strong predictor for the development of AIDS-related lymphoma: German CLINSURV Cohort [abstract 16]. In: 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston.
18. Gerard L, Galicier L, Maillard A, et al. Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival. J Acquir Immune Defic Syndr 2002; 30:478-484.
19. Boue F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol 2006; 24:4123-4128.
20. Wagner-Jonhston ND, Ambinder RF. Blood and marrow transplant for lymphoma patients with HIV/AIDS. Curr Opin Oncol 2008; 20:201-205.
21. Engels EA, Biggar RJ, Marshall VA, et al. Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kapo-si's sarcoma. AIDS 2003; 17:1847-1851.
22. Mocroft A, Kirk O, Clumeck N, et al. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the Euro SIDA Study. Cancer 2004; 100:2644-2654.
23. Connick E, Kane MA, White IE, et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy. Clin Infect Dis 2004; 39:1852-1855.
24. Sgadari C, Monini P, Barillari G, Ensoli B. Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncol 2003; 4:537-547.
25. Portsmouth S, Stebbing J, Gill J, et al. A comparison of regimens based on nonnucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 2003; 17:F17-F22.
26. Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol 2004; 22:399-402.
27. Dittmer DP, Krown SE. Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus. Curr Opin Oncol 2007; 19:452-457.
28. Dal Maso L, Serraino D, Franceschi S. Epidemiology of HIV-associated malignancies in developed and developing countries. Eur J Cancer 2001; 37:1188-1201.
29. Ahdieh-Grant L, Li R, Levine AM, et al. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst 2004; 96:1070-1076.
30. Heard I, Tassie JM, Kazatchkine MD, Orth G. Highly active antiretroviral therapy enhances regression of cervical intraepithelial neoplasia in HIV-seropositive women. AIDS 2002; 16:1799-1802.
31. Lillo FB, Ferrari D, Veglia F, et al. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis 2001; 184:547-551.
32. Schuman P, Ohmit SE, Klein RS, et al. Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2003; 188:128-136.
33. 2004 French guidelines for the management of HIV-infected people. Opportunistic infections and cancers. Medecine-Science Flammarion. Paris; 2004. pp. 227-254.
34. Bonnet F, Morlat P. Cancer and HIV infection: any association? Rev Med Interne 2006; 27:227-235.
35. Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001; 285:1736-1745.
36. Grulich AE, Li Y, Me Donald A, et al. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 2002; 16:1155-1161.
37. Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003; 21:3447-3453.
38. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425-432.
39. Patel P, Hanson D, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728-736. The latest large national study assessing the risk of nine types of cancers in HIV population compared with the general population between 1992 and 2003 and showing the evolution over three periods of time.
40. WIHS Collaborative Study Group. Cancer risk among participants in the women interagency HIV study. J Acquir Immune Defic Syndr 2004; 36:978-985.
41. Long JL, Engels EA, Moore RD, Gebo KA. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS 2008; 22:489-496.
42. Meng Q, Walker DM, Olivero OA, et al. Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells. Proc Natl Acad Sci U S A 2000; 97:12667-12671.
43. Chavan S, Kodoth S, Pahwa R, Pahwa S. The HIV protease inhibitor indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals. Blood 2001; 98:383-389.
44. Weichold FF, Bryant JL, Pati S, et al. HIV-1 protease-inhibitor ritonavir modulates susceptibility to apotptosis of uninfected T-cells. J Hum Virol 1999; 2:261-269.
45. Grulich AE, Wan X, Law MG, et al. Risk of cancer in patients with AIDS. AIDS 1999; 13:839-843.
46. Gallagher B, Wang Z, Schymura MJ, et al. Cancer incidence in New York State acquired immunodeficiency syndrome patients. Am J Epidemiol 2001; 154:544-556.
47. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59-67. A large meta-analysis suggesting for the first time that immune deficiency, rather than other risk factors for cancer, might be responsible for the higher risk of non-AIDS malignancies observed in individuals living with HIV.
48. Marin B, Thiebaut R, Rondeau V, et al. Association between CD4 and HIVRNA with non-AIDS related causes of death in the era combination antiretroviral therapy [abstract WePeB019]. In: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 22-25 July 2007; Sydney.
49. Knowles DM, Chamulack GA, Subar M, et al. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome. Ann Intern Med 1988; 108:744-753.
50. Hessol NA, Katz MH, Liu JY, et al. Increased incidence of Hodgkin disease in homosexual men with HIV infection. Ann Intern Med 1992; 117:309-311.
51. Gerard L, Galicier L, Boulanger E, et al. Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy. AIDS 2003; 17:81-87.
52. Hoffmann C, Chow KU, Wolf E, et al. Strong impact of HAART on survival in patients with HIV-associated Hodgkin's disease. Br J Haematol 2004; 125:455-462.
53. Vilchez RA, Finch CJ, Jorgensen JL, Butel JS. The clinical epidemiology of Hodgkin lymphoma in HIV-infected patients in the HAART era. Medicine 2003; 82:77-81.
54. Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006; 108:3786-3791.
55. Chaturvedi AK, Pfeiffer RM, Chang L, et al. Elevated risk of lung cancer among people with AIDS. AIDS 2007; 21:207-213. A large study assessing cancer risk in HIV-infected patients and the general population. Lung cancer risk was substantially elevated among HIV patients. Smoking could not entirely account for this trend, especially among younger adults, suggesting a role for additional cofactors.
56. Bower M, Powles T, Nelson M, et al. HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 2003; 17:371-375.
57. Benard A, Bonnet F, Tessier JF, et al. Tobacco addiction and HIV infection: toward the implementation of cessation programs. ANRS CO3 Aquitaine Cohort. AIDS Patient Care STDS 2007; 21:458-468.
58. Kirk GD, Merlo C, O'Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of cancer. Clin Infect Dis 2007; 45:103-110. A study showing that HIV infection was associated with a significantly higher risk of lung cancer independent of smoking status.
59. Tirelli U, Spina M, Sandri S, et al. Lung carcinoma in 36 patients with human immunodeficiency virus infection. The Italian cooperative group on AIDS and tumors. Cancer 2000; 88:563-569.
60. Alshafie MT, Donaldson B, Oluwole SF. Human immunodeficiency virus infection and lung cancer. Br J Surg 1997; 84:1068-1071.
61. Salmon-Ceron D, Lewden C, Morlat P, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42:799-805.
62. McGinnis KA, Fultz SL, Skanderson M, et al. Hepatocellular carcinoma and non-Hodgkin's lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse. J Clin Oncol 2006; 24:5005-5009.
63. Vogel J, Hinrichs S, Napolitano L, et al. Liver cancer in transgenic mice carrying the HIV tat gene. Cancer Res 1991; 51:6686-6690.
64. Puoti M, Bruno R, Soriano V, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004; 18:2285-2293.
65. Bräu N, Fox RK, Xiao P, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 2007; 47:527-537. A national study on hepatocarcinoma in HIV-infected patients showing that improved survival is independently associated with undetectable HIV RNA.
66. Sobhani I, Walker F, Roudot-Thoraval F, et al. Anal carcinoma: incidence and effect of cumulative infections. AIDS 2004; 18:1561-1569.
67. Bower M, Powles T, Newsom-Davis T, et al. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr 2004; 37:1563-1565.
68. Drobacheff C, Dupont P, Mougin C, et al. Anal human papillomavirus DNA screening by hybrid capture II in human immunodeficiency virus-positive patients with or without anal intercourse. Eur J Dermatol 2003; 13:367-371.
69. Piketty C, Darragh TM, Da Costa M, et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med 2003; 138:453-459.
70. Chiao EY, Giordano TP, Richardson P, El-Serag HB. Human immunodefi-ciency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol 2008; 3:474-479. A large prognostic study showing that survival of anal cancer is equivalent between HIV-positive and HIV-negative individuals in the cART era, and that treatment should not be withheld or deintensified on the basis of HIV status.
71. Conley U, Ellerbrock TV, Bush TJ, et al. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002; 359:108-113.
72. Powles T, Powles J, Nelson M, et al. Head and neck cancer in patients with human immunodeficiency virus-1 infection: incidence, outcome and association with Epstein-Barr virus. J Laryngol Otol 2004; 118:207-212.
73. Newton R, Ziegler J, Ateenyi-Agaba C, et al. The epidemiology of conjunctival squamous cell carcinoma in Uganda. Br J Cancer 2002; 87:301-308.
74. 3 after 6 years of cART can be identified and could reach the same prognosis as the uninfected population of the same age and sex.
75. Persad GC, Little RF, Grady C. Including persons with HIV infection in cancer clinical trials. J Clin Oncol 2008; 7:1027-1032.